Presence and short‐term persistence of SARS‐CoV ‐2 neutralizing antibodies in COVID ‐19 convalescent plasma donors-Reference-Cited by-同舟云学术

Presence and short‐term persistence of SARS‐CoV ‐2 neutralizing antibodies in COVID ‐19 convalescent plasma donors

Published:2021-01-16 Issue:4 Volume:61 Page:1148-1159
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Annen Kyle¹^ORCID,Morrison Thomas E.²,DomBourian Melkon G.¹,McCarthy Mary K.²,Huey Leah³,Merkel Patricia A.³,Andersen Gillian¹,Schwartz Eileen¹,Knight Vijaya³

Affiliation:

1. Department of Pathology and Laboratory Medicine University of Colorado School of Medicine and Childrenʼs Hospital Aurora Colorado USA

2. Department of Immunology and Microbiology University of Colorado School of Medicine Aurora Colorado USA

3. Department of Pediatrics, Section of Allergy and Immunology University of Colorado School of Medicine and Childrenʼs Hospital Aurora Colorado USA

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.16261

Reference39 articles.

1. U.S. Food & Drug Administration. Recommendations for investigational COVID‐19 convalescent plasma.https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma. Published November 16 2020. Accessed 02 12 2021.

2. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Investigational COVID‐19 convalescent plasma: guidance for industry.https://www.fda.gov/media/136798/download. Document issued November 16 2020. Accessed 08 23 2020.

3. U.S. Food & Drug Administration. FDA news release: FDA issues emergency use authorization for convalescent plasma as potential promising COVID‐19 treatment another achievement in administration's fight against pandemic.https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment. Released August 23 2020. Accessed 03 30 2020.

4. U.S. Food & Drug Administration. CFR – code of federal regulations title 21.https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=630.3. Page current as of April 1 2020. Accessed 11 10 2020.

5. Protein levels and plasmapheresis intensity

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection methods and dynamic characteristics of specific antibodies in patients with COVID-19: A review of the early literature;Heliyon;2024-02

2. An Overview of the Conventional and Novel Methods Employed for SARS-CoV-2 Neutralizing Antibody Measurement;Viruses;2023-07-05

3. Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies;Virology Journal;2023-03-27

4. Harmonization of Multiple SARS-CoV-2 Reference Materials Using the WHO IS (NIBSC 20/136): Results and Implications;Frontiers in Microbiology;2022-05-30

5. A quantitative assay for detection of SARS-CoV-2 neutralizing antibodies;Journal of Clinical Virology;2022-02